
Michael S Broder

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3377008/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	FIGO classification system (PALM OEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. International Journal of Gynecology and Obstetrics, 2011, 113, 3-13.	1.0	1,066
2	Health Information on the Internet. JAMA - Journal of the American Medical Association, 2001, 285, 2612.	3.8	1,013
3	Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses' Health Study. Obstetrics and Gynecology, 2009, 113, 1027-1037.	1.2	537
4	Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study. Obstetrics and Gynecology, 2013, 121, 709-716.	1.2	370
5	Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Advances, 2018, 2, 1046-1053.	2.5	260
6	Clinical Outcomes and Resource Utilization Associated With Laparoscopic and Open Colectomy Using a Large National Database. Annals of Surgery, 2008, 247, 819-824.	2.1	251
7	The FIGO Recommendations on Terminologies and Definitions for Normal and Abnormal Uterine Bleeding. Seminars in Reproductive Medicine, 2011, 29, 383-390.	0.5	250
8	Ovarian Conservation at the Time of Hysterectomy for Benign Disease. Obstetrics and Gynecology, 2005, 106, 219-226.	1.2	234
9	Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction. Clinical Infectious Diseases, 2004, 39, 1254-1255.	2.9	215
10	Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection. Seminars in Arthritis and Rheumatism, 2006, 36, 159-167.	1.6	207
11	A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleedingâ^—. Fertility and Sterility, 2007, 87, 466-476.	0.5	163
12	The appropriateness of recommendations for hysterectomy. Obstetrics and Gynecology, 2000, 95, 199-205.	1.2	145
13	Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. Journal of Medical Economics, 2018, 21, 127-134.	1.0	140
14	Healthcare utilization and costs in adults with stable and uncontrolled epilepsy. Epilepsy and Behavior, 2014, 31, 356-362.	0.9	130
15	Comparison of long-term outcomes of myomectomy and uterine artery embolization*1. Obstetrics and Gynecology, 2002, 100, 864-868.	1.2	108
16	Defining High-Quality Palliative Care in Oncology Practice: An American Society of Clinical Oncology/American Academy of Hospice and Palliative Medicine Guidance Statement. Journal of Oncology Practice, 2016, 12, e828-e838.	2.5	102
17	Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States. JBMR Plus, 2019, 3, e10192.	1.3	97
18	Healthcare utilization and costs in children with stable and uncontrolled epilepsy. Epilepsy and Behavior, 2014, 32, 135-141.	0.9	79

#	Article	IF	CITATIONS
19	Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulmonary Medicine, 2016, 16, 2.	0.8	75
20	Review of the confusion in current and historical terminology and definitions for disturbances of menstrual bleeding. Fertility and Sterility, 2008, 90, 2269-2280.	0.5	72
21	Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review. World Journal of Gastroenterology, 2015, 21, 1945.	1.4	71
22	Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis. Seminars in Arthritis and Rheumatism, 2016, 46, 246-252.	1.6	71
23	Cost, utilization, and patterns of medication use associated with chronic idiopathic urticaria. Annals of Allergy, Asthma and Immunology, 2012, 108, 98-102.	0.5	63
24	The Cost of Hematopoietic Stem-Cell Transplantation in the United States. American Health and Drug Benefits, 2017, 10, 366-374.	0.5	62
25	Elective oophorectomy for benign gynecological disorders. Menopause, 2007, 14, 580-585.	0.8	61
26	Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use. Allergy and Asthma Proceedings, 2015, 36, 268-274.	1.0	60
27	Ovarian Conservation at the Time of Hysterectomy for Benign Disease. Clinical Obstetrics and Gynecology, 2007, 50, 354-361.	0.6	59
28	Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients <65 years old in the United States. Pituitary, 2015, 18, 283-289.	1.6	56
29	Resource Use and Costs in an Insured Population of Patients with Chronic Idiopathic/Spontaneous Urticaria. American Journal of Clinical Dermatology, 2015, 16, 313-321.	3.3	55
30	Infant mortality and early postpartum discharge. Obstetrics and Gynecology, 2000, 96, 183-188.	1.2	49
31	Physician Survey of the Effect of the 21-Gene Recurrence Score Assay Results on Treatment Recommendations for Patients With Lymph Node–Positive, Estrogen Receptor–Positive Breast Cancer. Journal of Oncology Practice, 2011, 7, 94-99.	2.5	48
32	Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis. Journal of Medical Economics, 2013, 16, 801-808.	1.0	40
33	Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs. Value in Health, 2017, 20, 200-205.	0.1	39
34	Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400Âmg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data. Advances in Therapy, 2018, 35, 1612-1625.	1.3	31
35	Mechanical ventilation in idiopathic pulmonary fibrosis: a nationwide analysis of ventilator use, outcomes, and resource burden. BMC Pulmonary Medicine, 2017, 17, 84.	0.8	29
36	Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. World Journal of Gastroenterology, 2016, 22, 2118.	1.4	29

#	Article	IF	CITATIONS
37	An Agenda for Research into Uterine Artery Embolization: Results of an Expert Panel Conference. Journal of Vascular and Interventional Radiology, 2000, 11, 509-515.	0.2	27
38	Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer. American Journal of Managed Care, 2011, 17, 455-64.	0.8	27
39	Validation of an ICD-9–based claims algorithm for identifying patients with chronic idiopathic/spontaneous urticaria. Annals of Allergy, Asthma and Immunology, 2015, 114, 393-398.	0.5	25
40	Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 641-648.	0.7	25
41	Incidence and Prevalence of Acromegaly in the United States: A Claims-Based Analysis. Endocrine Practice, 2016, 22, 1327-1335.	1.1	25
42	Hospital cost and length of stay in idiopathic pulmonary fibrosis. Journal of Medical Economics, 2017, 20, 518-524.	1.0	25
43	Ratio of controller to total asthma medications: determinants of the measure. American Journal of Managed Care, 2010, 16, 170-8.	0.8	25
44	Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies. Oncologist, 2019, 24, 1229-1236.	1.9	24
45	Elective oophorectomy in the gynecological patient: when is it desirable?. Current Opinion in Obstetrics and Gynecology, 2007, 19, 350-354.	0.9	23
46	Biochemical Control During Long-Term Follow-Up of 230 Adult Patients with Cushing Disease: A Multicenter Retrospective Study. Endocrine Practice, 2017, 23, 962-970.	1.1	23
47	Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: A guideline for primary care physicians from the National Stroke Association work group on recurrent stroke prevention. Journal of Stroke and Cerebrovascular Diseases, 2004, 13, 196-207.	0.7	22
48	Systemic Treatment in Unresectable Metastatic Well-Differentiated Carcinoid Tumors. Pancreas, 2013, 42, 397-404.	0.5	21
49	Cost and utilization of COPD and asthma among insured adults in the US. Current Medical Research and Opinion, 2009, 25, 1385-1392.	0.9	20
50	A Five-Year International Review Process Concerning Terminologies, Definitions, and Related Issues around Abnormal Uterine Bleeding. Seminars in Reproductive Medicine, 2011, 29, 377-382.	0.5	20
51	Burden of disease in pediatric narcolepsy: a claims-based analysis of health care utilization, costs, and comorbidities. Sleep Medicine, 2020, 66, 110-118.	0.8	20
52	Poor disease control among insured users of high-dose combination therapy for asthma. Allergy and Asthma Proceedings, 2010, 31, 60-67.	1.0	19
53	Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Current Rheumatology Reports, 2005, 7, 3-9.	2.1	17
54	Incremental healthcare resource utilization and costs in US patients with Cushing's disease compared with diabetes mellitus and population controls. Pituitary, 2015, 18, 796-802.	1.6	16

#	Article	IF	CITATIONS
55	Corticosteroid-related toxicity in patients with chronic idiopathic urticariaâ€chronic spontaneous urticaria. Allergy and Asthma Proceedings, 2016, 37, 458-465.	1.0	16
56	The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail. Oncologist, 2017, 22, 379-385.	1.9	16
57	Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis. Advances in Therapy, 2017, 34, 2093-2103.	1.3	15
58	Epidemiology of Gastrointestinal Neuroendocrine Tumors in a U.S. Commercially Insured Population. Endocrine Practice, 2017, 23, 1210-1216.	1.1	15
59	Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting. Journal of Managed Care & Specialty Pharmacy, 2017, 23, S34-S48.	0.5	15
60	Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy. BMC Ophthalmology, 2021, 21, 327.	0.6	15
61	An International Response to Questions about Terminologies, Investigation, and Management of Abnormal Uterine Bleeding: Use of an Electronic Audience Response System. Seminars in Reproductive Medicine, 2011, 29, 436-445.	0.5	14
62	Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer. Current Medical Research and Opinion, 2014, 30, 321-328.	0.9	14
63	Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database. BMC Pulmonary Medicine, 2018, 18, 135.	0.8	14
64	Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia. Journal of Medical Economics, 2012, 15, 105-111.	1.0	13
65	Clinical and economic impact of adhesiolysis during repeat cesarean delivery. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 719-725.	1.3	13
66	<p>Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States</p> . ClinicoEconomics and Outcomes Research, 2019, Volume 11, 431-439.	0.7	13
67	Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections. Journal of Rheumatology, 2004, 31, 1888-92.	1.0	13
68	Postpartum Length of Stay and Newborn Health: A Cost-Effectiveness Analysis. Pediatrics, 2003, 111, e316-e322.	1.0	12
69	Health and economic outcomes associated with uncontrolled surgical bleeding: a retrospective analysis of the Premier Perspectives Database. ClinicoEconomics and Outcomes Research, 2015, 7, 409.	0.7	12
70	<p>Development of a Severity Classification System for Sickle Cell Disease</p> . ClinicoEconomics and Outcomes Research, 2020, Volume 12, 625-633.	0.7	12
71	An Adaptation of the RAND/UCLA Modified Delphi Panel Method in the Time of COVID-19. Journal of Healthcare Leadership, 0, Volume 14, 63-70.	1.5	12
72	Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naÃ ⁻ ve human immunodeficiency virus-infected patients in the United States. Journal of Medical Economics, 2011, 14, 167-178.	1.0	11

#	Article	IF	CITATIONS
73	All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics. Current Medical Research and Opinion, 2018, 34, 41-47.	0.9	11
74	Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. World Journal of Gastroenterology, 2015, 21, 2450.	1.4	11
75	The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature. American Health and Drug Benefits, 2014, 7, 171-82.	0.5	11
76	Systematic bias in predictions of new drugs' budget impact: analysis of a sample of recent US drug launches. Current Medical Research and Opinion, 2018, 34, 765-773.	0.9	10
77	Measures of surgical quality: what will patients know by 2005?. Journal of Evaluation in Clinical Practice, 2005, 11, 209-217.	0.9	9
78	Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use. Epilepsy and Behavior, 2015, 44, 40-46.	0.9	9
79	Cost of cancer management by stage at diagnosis among Medicare beneficiaries. Current Medical Research and Opinion, 2022, 38, 1285-1294.	0.9	9
80	Cost and health care utilization in patients with asthma and high oral corticosteroid use. Annals of Allergy, Asthma and Immunology, 2017, 118, 638-639.	0.5	8
81	Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence. Leukemia Research, 2017, 60, 123-128.	0.4	8
82	Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis. World Journal of Gastroenterology, 2017, 23, 6128-6136.	1.4	8
83	Care of asthma patients in relation to guidelines. Allergy and Asthma Proceedings, 2010, 31, 452-460.	1.0	7
84	Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis. Journal of Comparative Effectiveness Research, 2020, 9, 933-943.	0.6	7
85	First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA. Journal of Medical Economics, 2018, 21, 821-826.	1.0	6
86	Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment. Clinical Therapeutics, 2019, 41, 221-232.	1.1	6
87	Concomitant Asthma Medication Use by Patients Receiving Omalizumab 2003–2008. Journal of Asthma, 2011, 48, 1058-1062.	0.9	5
88	Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US. ClinicoEconomics and Outcomes Research, 2013, 5, 437.	0.7	5
89	Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. BMC Health Services Research, 2014, 14, 429.	0.9	5
90	Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database Analysis. Oncology, 2018, 94, 281-288.	0.9	5

#	Article	IF	CITATIONS
91	The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data. Neurology and Therapy, 2020, 9, 473-482.	1.4	5
92	<p>Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder</p> . ClinicoEconomics and Outcomes Research, 2020, Volume 12, 81-89.	0.7	4
93	Treatment patterns for women with new episodes of uterine myomas in an insured population in the US. Current Medical Research and Opinion, 2006, 22, 95-100.	0.9	2
94	Treatment adherence, healthcare resource utilization, and costs in patients with lung neuroendocrine tumors (lung NETs) in the USA. Current Medical Research and Opinion, 2018, 34, 2151-2156.	0.9	2
95	Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use. Journal of Comparative Effectiveness Research, 2022, 11, 575-582.	0.6	1
96	Real-world impact of disease on functioning and activity: what is missed when using general instruments to estimate quality-adjusted life years. Current Medical Research and Opinion, 2022, 38, 165-170.	0.9	0
97	A method classifying biologics for formulary decision making. Managed Care Interface, 2006, 19, 30-2.	0.2	0
98	Biologic Initiation Rate in Systemic-NaÃ ⁻ ve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database. Open Access Rheumatology: Research and Reviews, 0, Volume 14, 123-132.	0.8	0